Format

Send to

Choose Destination
Nephrol Dial Transplant. 2017 Aug 1;32(8):1373-1386. doi: 10.1093/ndt/gfx011.

Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.

Author information

1
Institute of Nephrology, Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
2
Renji Hospital, Shanghai, China.
3
Zhejiang University, Hangzhou, China.
4
Sun Yat-Sen University, Guangzhou, China.
5
Changzheng Hospital, Shanghai, China.
6
Shanghai Huashan Hospital, Shanghai, China.
7
Xinhua Hospital, Jiaotong University, Shanghai, China.
8
Dalian Medical University, Dalian, China.
9
Shenzhen People's Hospital, Shenzhen, China.
10
Beijing University First Hospital, Beijing, China.
11
Sichuan Province Hospital, Chengdu, China.
12
West China Hospital, Chengdu, China.
13
Union Medical College Hospital, Beijing, China.
14
FibroGen, Inc., San Francisco, CA, USA.

Abstract

Background:

FG-4592 (roxadustat) is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (HIF-PHI) promoting coordinated erythropoiesis through the transcription factor HIF. Two Phase 2 studies were conducted in China to explore the safety and efficacy of FG-4592 (USAN name: roxadustat, CDAN name: ), a HIF-PHI, in patients with anemia of chronic kidney disease (CKD), both patients who were dialysis-dependent (DD) and patients who were not dialysis-dependent (NDD).

Methods:

In the NDD study, 91 participants were randomized to low (1.1-1.75 mg/kg) or high (1.50-2.25 mg/kg) FG-4592 starting doses or to placebo. In the DD study, 87 were enrolled to low (1.1-1.8 mg/kg), medium (1.5-2.3 mg/kg) and high (1.7-2.3 mg/kg) starting FG-4592 doses or to continuation of epoetin alfa. In both studies, only oral iron supplementation was allowed.

Results:

In the NDD study, hemoglobin (Hb) increase ≥1 g/dL from baseline was achieved in 80.0% of subjects in the low-dose cohort and 87.1% in the high-dose cohort, versus 23.3% in the placebo arm (P < 0.0001, both). In the DD study, 59.1%, 88.9% (P = 0.008) and 100% (P = 0.0003) of the low-, medium- and high-dose subjects maintained their Hb levels after 5- and 6-weeks versus 50% of the epoetin alfa-treated subjects. In both studies, significant reductions in cholesterol were noted in FG-4592-treated subjects, with stability or increases in serum iron, total iron-binding capacity (TIBC) and transferrin (without intravenous iron administration). In the NDD study, hepcidin levels were significantly reduced across all FG-4592-treated arms as compared with no change in the placebo arm. In the DD study, hepcidin levels were also reduced in a statistically significant dose-dependent manner in the highest dose group as compared with the epoetin alfa-treated group. Adverse events were similar for FG-4592-treated and control subjects.

Conclusions:

FG-4592 may prove an effective alternative for managing anemia of CKD. It is currently being investigated in a pivotal global Phase 3 program.

KEYWORDS:

FG-4592; anemia in chronic kidney disease; erythropoiesis; erythropoietin; hypoxia-inducible factor

PMID:
28371815
PMCID:
PMC5837707
DOI:
10.1093/ndt/gfx011
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center